Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Model representations of performance on functional and behavioral measures over time for behavioral variant frontotemporal dementia (bvFTD) and.

Published byJerome Welch Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2 Model representations of performance on functional and behavioral measures over time for behavioral variant frontotemporal dementia (bvFTD) and."— Presentation transcript:

1 Figure 2 Model representations of performance on functional and behavioral measures over time for behavioral variant frontotemporal dementia (bvFTD) and sematic variant primary progressive aphasia (svPPA) (plots model representations of scores)‏ Model representations of performance on functional and behavioral measures over time for behavioral variant frontotemporal dementia (bvFTD) and sematic variant primary progressive aphasia (svPPA) (plots model representations of scores) (A–G) ADL = activities of daily living; BADL = basic activities of daily living; CBI = Cambridge Behavioural Inventory; DAD = Disability Assessment for Dementia; IADL = instrumental activities of daily living. Claire M. O'Connor et al. Neurol Clin Pract 2016;6: © 2016 American Academy of Neurology

Download ppt "Figure 2 Model representations of performance on functional and behavioral measures over time for behavioral variant frontotemporal dementia (bvFTD) and."

Similar presentations

Frontotemporal dementia syndromes are united by underlying frontotemporal lobar degeneration pathology, which can be divided according to the presence.

Frontotemporal dementia syndromes are united by underlying frontotemporal lobar degeneration pathology, which can be divided according to the presence.
Copyright © American Speech-Language-Hearing Association

Copyright © American Speech-Language-Hearing Association
A 66 year-old woman with progressive speech difficulty

A 66 year-old woman with progressive speech difficulty
Figure Flow of funds for a 340B agreement for fingolimod

Figure Flow of funds for a 340B agreement for fingolimod
Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 4 Cerebrospinal fluid levels of neurofilament light chain

Figure 4 Cerebrospinal fluid levels of neurofilament light chain
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 2. Infliximab treatment effect

Figure 2. Infliximab treatment effect
Figure 1 Box plot of the venous diameter in lesions

Figure 1 Box plot of the venous diameter in lesions
Volume 7, Issue 12, Pages (December 2015)

Volume 7, Issue 12, Pages (December 2015)
Figure 2 Grey matter atrophy in FTD

Figure 2 Grey matter atrophy in FTD
Figure 2 Flow chart of patients who met the inclusion/exclusion criteria for the study Flow chart of patients who met the inclusion/exclusion criteria.

Figure 2 Flow chart of patients who met the inclusion/exclusion criteria for the study Flow chart of patients who met the inclusion/exclusion criteria.
Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.

Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.
Figure 3 Genetic pleiotropy in ALS

Figure 3 Genetic pleiotropy in ALS
Figure 2 FXTAS Rating Scale scores for case 1

Figure 2 FXTAS Rating Scale scores for case 1
Figure Pedigree of the family

Figure Pedigree of the family
Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.
Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists.

Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists.
Figure 3 Transcripts of the splicing mutation (c

Figure 3 Transcripts of the splicing mutation (c

Similar presentations

Ads by Google